amlodipine has been researched along with Iron Overload in 13 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Iron Overload: An excessive accumulation of iron in the body due to a greater than normal absorption of iron from the gastrointestinal tract or from parenteral injection. This may arise from idiopathic hemochromatosis, excessive iron intake, chronic alcoholism, certain types of refractory anemia, or transfusional hemosiderosis. (From Churchill's Illustrated Medical Dictionary, 1989)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The use of amlodipine in conjunction with standard chelation therapy may suggest a new strategy in preventing and treating iron overload in patients with thalassemia major, especially in organs where iron absorption depends on active uptake by calcium channels like the heart." | 9.17 | Amlodipine reduces cardiac iron overload in patients with thalassemia major: a pilot trial. ( Coelho, OR; Fernandes, JL; Fertrin, K; Loggetto, S; Piga, A; Saad, ST; Sampaio, EF; Verissimo, M, 2013) |
| "Despite the growing evidence supporting the role of amlodipine in reducing iron overload in thalassaemia patients, our meta-analysis did not find that evidence collectively significant." | 9.12 | Amlodipine as adjuvant therapy to current chelating agents for reducing iron overload in thalassaemia major: a systematic review, meta-analysis and simulation of future studies. ( Abbas, AS; Alhusseiny, A; Ebied, A; Elfaituri, MK; Fernandes, JL; Ghozy, S; Hassan, OG; Huy, NT; Morra, ME; Sherif, NA, 2021) |
| " Amlodipine, L-type calcium channel blocker with regular chelation therapy may reduce myocardial iron overload." | 5.51 | Comparison of the effects of calcium channel blockers plus iron chelation therapy versus chelation therapy only on iron overload in children and young adults with transfusion-dependent thalassemia: A randomized double-blind placebo-controlled trial. ( Aggarwal, P; Agrawal, V; Gupta, V; Kumar, I; Raj, V, 2022) |
| "Our meta-analysis found that amlodipine significantly increases cardiac T2* and decreases MIC, hence decreasing the incidence of cardiomyopathy-related iron overload in thalassemia patients." | 5.41 | Efficacy and safety of calcium channel blockers in preventing cardiac siderosis in thalassemia patients: An updated meta-analysis with trial sequential analysis. ( Abdelaziz, A; Abdelwahab, OA; Amer, BE; Badawy, MM; Diab, RA; Elsharkawy, A; Goudy, YM; Mouffokes, A; Soliman, Y, 2023) |
| "The addition of amlodipine to the standard chelation therapy in transfusion-dependent thalassemia major patients improves myocardial iron overload without increasing the adverse effects." | 5.30 | A randomized controlled trial evaluating the effects of amlodipine on myocardial iron deposition in pediatric patients with thalassemia major. ( Ezzat, DA; Khaled, A; Rabee, H; Salem, HA; Seif, HM, 2019) |
| "The use of amlodipine in conjunction with standard chelation therapy may suggest a new strategy in preventing and treating iron overload in patients with thalassemia major, especially in organs where iron absorption depends on active uptake by calcium channels like the heart." | 5.17 | Amlodipine reduces cardiac iron overload in patients with thalassemia major: a pilot trial. ( Coelho, OR; Fernandes, JL; Fertrin, K; Loggetto, S; Piga, A; Saad, ST; Sampaio, EF; Verissimo, M, 2013) |
| "Despite the growing evidence supporting the role of amlodipine in reducing iron overload in thalassaemia patients, our meta-analysis did not find that evidence collectively significant." | 5.12 | Amlodipine as adjuvant therapy to current chelating agents for reducing iron overload in thalassaemia major: a systematic review, meta-analysis and simulation of future studies. ( Abbas, AS; Alhusseiny, A; Ebied, A; Elfaituri, MK; Fernandes, JL; Ghozy, S; Hassan, OG; Huy, NT; Morra, ME; Sherif, NA, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 6 (46.15) | 2.80 |
| Authors | Studies |
|---|---|
| Gupta, V | 1 |
| Kumar, I | 1 |
| Raj, V | 1 |
| Aggarwal, P | 1 |
| Agrawal, V | 1 |
| Soliman, Y | 1 |
| Abdelaziz, A | 1 |
| Mouffokes, A | 1 |
| Amer, BE | 1 |
| Goudy, YM | 1 |
| Abdelwahab, OA | 1 |
| Badawy, MM | 1 |
| Diab, RA | 1 |
| Elsharkawy, A | 1 |
| Padhani, ZA | 1 |
| Gangwani, MK | 1 |
| Sadaf, A | 3 |
| Hasan, B | 2 |
| Colan, S | 3 |
| Alvi, N | 3 |
| Das, JK | 2 |
| Khaled, A | 1 |
| Salem, HA | 1 |
| Ezzat, DA | 1 |
| Seif, HM | 1 |
| Rabee, H | 1 |
| Alali, MA | 1 |
| Alanazi, KMA | 1 |
| Alsayil, SN | 1 |
| Omari, Z | 1 |
| Shaaban, A | 1 |
| Elfaituri, MK | 1 |
| Ghozy, S | 1 |
| Ebied, A | 1 |
| Morra, ME | 1 |
| Hassan, OG | 1 |
| Alhusseiny, A | 1 |
| Abbas, AS | 1 |
| Sherif, NA | 1 |
| Fernandes, JL | 2 |
| Huy, NT | 1 |
| Karami, H | 1 |
| Khalilzadeh Arjmandi, H | 1 |
| Salehifar, E | 1 |
| Darvishi-Khezri, H | 1 |
| Dabirian, M | 1 |
| Kosaryan, M | 1 |
| Aliasgharian, A | 1 |
| Akbarzadeh, R | 1 |
| Naeimayi Aali, R | 1 |
| Nasirzadeh, A | 1 |
| Eghbali, A | 1 |
| Kazemi, H | 1 |
| Taherahmadi, H | 1 |
| Ghandi, Y | 1 |
| Rafiei, M | 1 |
| Bagheri, B | 1 |
| Sampaio, EF | 1 |
| Fertrin, K | 1 |
| Coelho, OR | 1 |
| Loggetto, S | 1 |
| Piga, A | 1 |
| Verissimo, M | 1 |
| Saad, ST | 1 |
| Shakoor, A | 1 |
| Zahoor, M | 1 |
| Fadoo, Z | 1 |
| Rizvi, A | 1 |
| Quadri, F | 1 |
| Tipoo, FA | 1 |
| Khurshid, M | 1 |
| Sajjad, Z | 1 |
| Hasan, BS | 1 |
| Oudit, GY | 2 |
| Backx, PH | 2 |
| Sun, H | 1 |
| Trivieri, MG | 1 |
| Koch, SE | 1 |
| Dawood, F | 1 |
| Ackerley, C | 1 |
| Yazdanpanah, M | 1 |
| Wilson, GJ | 1 |
| Schwartz, A | 1 |
| Liu, PP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of L-type Calcium Channel Blocker (Amlodipine) on Myocardial Iron Deposition in Thalassemic Patients With Moderate to Severe Myocardial Iron Deposition: A Randomized Pilot Study[NCT02065492] | Phase 2/Phase 3 | 20 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for amlodipine and Iron Overload
| Article | Year |
|---|---|
Efficacy and safety of calcium channel blockers in preventing cardiac siderosis in thalassemia patients: An updated meta-analysis with trial sequential analysis.
Topics: Amlodipine; beta-Thalassemia; Calcium Channel Blockers; Humans; Iron; Iron Chelating Agents; Iron Ov | 2023 |
Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia.
Topics: Amlodipine; beta-Thalassemia; Calcium Channel Blockers; Cardiomyopathies; Child; Edema; Ferritins; H | 2023 |
Calcium Channel Blockers in Conjunction with Standard Iron-Chelating Agents for β-Thalassemia Major: Systematic Literature Search.
Topics: Amlodipine; beta-Thalassemia; Biomarkers; Calcium Channel Blockers; Chelation Therapy; Drug Therapy, | 2020 |
Amlodipine as adjuvant therapy to current chelating agents for reducing iron overload in thalassaemia major: a systematic review, meta-analysis and simulation of future studies.
Topics: Amlodipine; beta-Thalassemia; Humans; Iron Chelating Agents; Iron Overload; Thalassemia | 2021 |
Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia.
Topics: Adolescent; Adult; Amlodipine; beta-Thalassemia; Blood Transfusion; Calcium Channel Blockers; Cardio | 2018 |
6 trials available for amlodipine and Iron Overload
| Article | Year |
|---|---|
Comparison of the effects of calcium channel blockers plus iron chelation therapy versus chelation therapy only on iron overload in children and young adults with transfusion-dependent thalassemia: A randomized double-blind placebo-controlled trial.
Topics: Amlodipine; beta-Thalassemia; Calcium Channel Blockers; Chelation Therapy; Child; Ferritins; Humans; | 2022 |
A randomized controlled trial evaluating the effects of amlodipine on myocardial iron deposition in pediatric patients with thalassemia major.
Topics: Adolescent; Adult; Amlodipine; beta-Thalassemia; Calcium Channel Blockers; Child; Female; Humans; Ir | 2019 |
A double-blind, controlled, crossover trial of amlodipine on iron overload status in transfusion dependent β-thalassemia patients.
Topics: Amlodipine; beta-Thalassemia; Chelation Therapy; Cross-Over Studies; Humans; Iron Overload; Liver; M | 2021 |
A randomized, controlled study evaluating effects of amlodipine addition to chelators to reduce iron loading in patients with thalassemia major.
Topics: Adolescent; Adult; Amlodipine; beta-Thalassemia; Biomarkers; Cardiomyopathies; Chelation Therapy; Ch | 2017 |
Amlodipine reduces cardiac iron overload in patients with thalassemia major: a pilot trial.
Topics: Adolescent; Adult; Amlodipine; Analysis of Variance; beta-Thalassemia; Calcium Channel Blockers; Che | 2013 |
Effect of L-type calcium channel blocker (amlodipine) on myocardial iron deposition in patients with thalassaemia with moderate-to-severe myocardial iron deposition: protocol for a randomised, controlled trial.
Topics: Adolescent; Amlodipine; Calcium Channel Blockers; Calcium Channels, L-Type; Cardiomyopathies; Chelat | 2014 |
2 other studies available for amlodipine and Iron Overload
| Article | Year |
|---|---|
Amlodipine Therapy for Iron-Overload Cardiomyopathy: The Enduring Value of Translational Research.
Topics: Amlodipine; Cardiomyopathies; Humans; Iron; Iron Overload; Translational Research, Biomedical | 2016 |
L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy.
Topics: Amlodipine; Animals; Biological Transport; Calcium Channel Blockers; Calcium Channels; Cardiomyopath | 2003 |